Cambridge Epigenetix introduces TrueMethyl Whole Genome integrated workflow for epigenetic analysis
Cambridge, UK, October 18, 2016: Cambridge Epigenetix (CEGX), a pioneer in the development of epigenetic sequencing technologies, today announced the launch of its TrueMethyl® Whole Genome (TMWG) integrated workflow system for processing DNA samples. The new system includes all-in-one reagents for sample conversion, library creation and indexing, combined with bioinformatic tools to enable accurate DNA modification analysis, designed to reduce experimental costs and improve the ease and accessibility of bisulfite sequencing for researchers. The workflow has been specifically designed to allow the technology to be accessible to researchers studying DNA modifications through next generation sequencing methods.
The TMWG kit incorporates CEGX’s TrueMethyl oxidative bisulfite (oxBS) technology, which allows researchers to accurately quantify different DNA modifications at single-base resolution, and proprietary library preparation methods, which have been designed to overcome the limitations of traditional bisulfite library construction to improve the yield and quality of epigenetic data. The bioinformatic tools comprise a series of scripts for QC analysis and biological analysis of the resultant sequencing data.
Dr Geoff Smith, CEO at Cambridge Epigenetix, commented: “The launch of TMWG opens up new opportunities in epigenetics research by allowing customers the ability to access the power of whole genome epigenetic information in an integrated, cost-effective solution that combines state-of-the art sample preparation and DNA sequence analysis. Working in collaboration with leading research groups, we have demonstrated that TMWG provides unprecedented levels of data accuracy of DNA modifications at base-pair resolution and at genome-wide level, and we look forward to supporting our customers in unlocking the tremendous potential of epigenetics.”
Notes to Editors:
Phone : +44 (0)7811 996 942
About Cambridge Epigenetix
CEGX, a life sciences company spun out from the University of Cambridge, was co-founded in 2012 by Professor Shankar Balasubramanian FRS and Dr. Bobby Yerramilli-Rao. The company’s founding technology, ox-BS sequencing, allows end-users to discriminate between 5-hydroxymethylcytosine (5hmC) and 5-methylcytosine (5mC) at a single-base resolution, which was previously impossible with traditional bisulfite sequencing methods. It has since developed a number of complementary technologies and seeks to capitalize on a wide set of applications in life sciences, as well as continue to develop breakthrough epigenetics tools. For more information, visit www.cambridge-epigenetix.com